Assessment of treatment options for patients with hepatitis C virus recombinant form 2k/1b.
HCV
RF_2k/1b
genotype
sofosbuvir
sustained virologic response
Journal
Hepatology research : the official journal of the Japan Society of Hepatology
ISSN: 1386-6346
Titre abrégé: Hepatol Res
Pays: Netherlands
ID NLM: 9711801
Informations de publication
Date de publication:
Feb 2021
Feb 2021
Historique:
received:
29
07
2020
revised:
21
10
2020
accepted:
24
10
2020
pubmed:
19
11
2020
medline:
19
11
2020
entrez:
18
11
2020
Statut:
ppublish
Résumé
Hepatitis C virus (HCV) intergenotype recombinant form (RF) 2k/1b has been actively circulating in HCV-infected patients, and the prevalence of this RF virus in the Republic of Georgia is one of the highest reported worldwide. The aim of this study was to define the optimal treatment regimen for patients with RF_2k/1b. We analyzed the data of 2735 patients who started treatment at the Medical Center Mrcheveli within Georgia's hepatitis C elimination program from May 2015 through December 2019. The patients were treated with sofosbuvir (SOF)-based regimens. For identification of RF_2k/1b variants, refinement of standard (INNO-LiPA) genotyping results for all patient samples assigned the unspecific HCV genotypes (GT) 2a/2c was carried out by sequencing of core and non-structural protein 5B genes. Overall, 444 patients, representing 66% of GT2 and 16% of the total samples, were RF_2k/1b. Treatment of patients with RF_2k/1b with SOF/ledipasvir and SOF/velpatasvir was highly effective and viral cure rates did not differ among genotypes treated with the same regimen: RF_2k/1b, 99% (343/346); GT1, 99% (876/885); GT2, 96% (156/162); and GT3, 99% (545/552). A separate comparison analysis of sustained virologic response rate, treated with SOF plus ribavirin, showed significantly higher sustained virologic response (96%) in patients with confirmed GT2 (by sequencing) compared to unspecified GT2 (by INNO-LiPA) (79%) (P < 0.05). Sofosbuvir-based regimens are highly effective for treatment of RF 2k/1b patients, and with availability of new pan-genotypic direct-acting antivirals, genotyping to identify RF 2k/1b patients might not be necessary.
Types de publication
Journal Article
Langues
eng
Pagination
156-165Subventions
Organisme : Medical Center Mrcheveli
Organisme : Medical Service Center Dr. Limbach & colleagues
Informations de copyright
© 2020 The Japan Society of Hepatology.
Références
Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17: 107-115.
World Health Organization. Global hepatitis report, 2017. Available at: https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/ Accessed March 18, 2020.
Nasrullah M, Sergeenko D, Gamkrelidze A, Averhoff F. HCV elimination - lessons learned from a small Eurasian country, Georgia. Nat Rev Gastroenterol Hepatol 2017; 14: 447-448.
Gvinjilia L, Nasrullah M, Sergeenko D et al. National progress toward hepatitis C elimination - Georgia, 2015-2016. MMWR Morb Mortal Wkly Rep 2016; 65: 1132-1135.
Mitruka K, Tsertsvadze T, Butsashvili M et al. Launch of a nationwide hepatitis C elimination program - Georgia, April 2015. MMWR Morb Mortal Wkly Rep 2015; 65: 753-757.
Walker JG, Kuchuloria T, Sergeenko D et al. Interim effect evaluation of the hepatitis C elimination programme in Georgia: a modelling study. Lancet Glob Health 2020; 8: e244-e253.
Tsertsvadze T, Gamkrelidze A, Chkhartishvili N et al. Three years of progress toward achieving hepatitis C elimination in the country of Georgia, April 2015-March 2018. Clin Infect Dis 2020; 71: 1263-1268.
Zakalashvili M, Weizenegger M, Bartel J et al. Emergence of hepatitis C virus genotype recombinant forms 2k/1b in Georgia. Clin Lab 2016; 62: 1347-1351.
Zakalashvili M, Zarkua J, Weizenegger M et al. Identification of hepatitis C virus 2k/1b intergenotypic recombinants in Georgia. Liver Int 2018; 38: 451-457.
Hedskog C, Doehle B, Chodavarapu K et al. Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin. Hepatology 2015; 61: 471-480.
Susser S, Dietz J, Schlevogt B et al. Origin, prevalence and response to therapy of hepatitis C virus genotype 2k/1b chimeras. J Hepatol 2017; 76: 680-686.
European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2018. J Hepatol 2018; 69: 461-511.
Smith DB, Bukh J, Kuiken C et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology 2014; 59: 318-327.
Kalinina O, Norder H, Mukomolov S, Magnius LO. A natural intergenotypic recombinant of hepatitis C virus identified in St. Petersburg. J Virol 2002; 76: 4034-4043.
Morel V, Fournier C, Francois C et al. Genetic recombination of the hepatitis C virus: clinical implications. J Viral Hepat 2011; 18: 77-83.
Raghwani J, Thomas XV, Koekkoek SM et al. Origin and evolution of the unique hepatitis C virus circulating recombinant form 2k/1b. J Virol 2012; 86: 2212-2220.
Paolucci S, Premoli M, Ludovisi S, Mondelli MU, Baldanti F. HCV intergenotype 2k/1b recombinant detected in a DAA-treated patient in Italy. Antivir Ther 2017; 22: 365-368.
Kassela K, Karakasiliotis I, Kokkiou E et al. Intergenotypic 2k/1b hepatitis C virus recombinants in the East Macedonia and Thrace region of Greece. Ann Gastroenterol 2019; 32: 88-92.
Hazzan R, Reish I, Barak M, Daniel R, Strauss M, Zuckerman E. Twelve weeks treatment with ombitasvir/paritaprevir/ritonavir and dasabuvir in chronic hepatitis C genotype 2k/1b patients is highly efficient and safe. Ann Clin Hepatol 2019; 3: 1010.
Karchava M, Chkhartishvili N, Sharvadze L et al. Impact of hepatitis C virus recombinant form RF1_2k/1b on treatment outcomes within the Georgian national hepatitis C elimination program. Hepatol Res 2018; 48: 36-44.
European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol 2015; 63: 199-236.
Tsertsvadze T, Gamkrelidze A, Nasrullah M et al. Treatment outcomes of patients with chronic hepatitis C receiving sofosbuvir-based combination therapy within national hepatitis C elimination program in the country of Georgia. BMC Infect Dis 2020; 20: 30.
Hézode C. Pan-genotypic treatment regimens for hepatitis C virus: advantages and disadvantages in high- and low-income regions. J Viral Hepat 2017; 24: 92-101.
Pawlotsky JM. DAA failures in African patients with “unusual” HCV subtypes: Hey! Didn't you know there was another world? J Hepatol 2019; 71: 1070-1072.